News

February 21, 2022

(LOS ANGELES) – Vadim Jucaud, Ph.D., Assistant Professor at the Terasaki Institute for Biomedical Innovation (TIBI), has been awarded an Early Career Investigator grant from METAvivor. This volunteer-led, non-profit organization supports vital research to benefit stage IV metastatic breast cancer (mBC) patients. METAvivor is dedicated to improving the longevity and quality of life of these patients and is the only organization in the United States that annually funds this type of research. The grant will fund a project titled

“Microengineered Approach to Develop Personalized Monoclonal Antibodies for Metastatic Breast Cancer Treatment.”

Read more ...

February 20, 2022

(LOS ANGELES) – In 1900, David Hilbert, a German Mathematician, developed a list of “mathematical problems” that had gone unsolved. He presented this list to an international society of mathematicians, which created a focus on the energy, time, and funding to solve these problems. In essence, the concept of Grand Challenges was born.

TumSince then, this idea of catalyzing communities of researchers to focus on the most challenging problems facing their respective fields has blossomed on an international scale. Nearly every foundation, academic institution, government, and even some private industry groups have used the Grand Challenges process to stimulate new ideas and galvanize their members to focus on these intractable issues.

Read more ...

Scientists delineate process which drives tumor formation by Kras oncogenes

February 8, 2022

(LOS ANGELES) – Cancerous tumors are made up of rapidly growing, abnormally shaped, cells that can infiltrate and destroy healthy tissues, travel to other parts of the body, and form additional tumors. In part because of its rapid and invasive nature, cancer remains the second leading cause of death in the United States and a major cause of death worldwide.

Tumor formation is often driven by genes called oncogenes, which are usually involved in the normal processes of cell growth, proliferation, and death. But they can also mutate and be expressed at high levels, which can drive the multiplication of cancerous cells.

Read more ...

January 12, 2022

(LOS ANGELES) – The Terasaki Institute for Biomedical Innovation (TIBI), a non-profit multidisciplinary bioengineering research institution, announces their partnership with Darling Ingredients’ health brand, Rousselot®, the world leader in collagen-based solutions, with more than 130 years of gelatin and collagen expertise.

With their long-standing experience in tissue engineering and regeneration, bio-fabrication using 3D printing and engineering micro- and nano-scale medical devices, TIBI has relied heavily on the use of modified and functionalized gelatin biomaterials for their research and experimentation. In doing so, they have developed valuable insights into gelatin’s behavior and have used this knowledge to optimize and tune gelatin biomaterials for various biomedical applications.

Read more ...

Scientists develop plant-based “hairy nanocrystals” to remove excess chemotherapy drugs from the blood

January 6, 2022

(LOS ANGELES) – Millions of people around the globe are affected by cancer each year; more than 39% of men and women are diagnosed with cancer during their lifetime. Chemotherapy is the most commonly employed, standard cancer treatment and targeted delivery of these drugs to the tumor site increases their effectiveness. However, excess drugs may still circulate to the rest of the body and cause multiple side effects, including anemia, chronic infections, hair loss, jaundice and fever.

Read more ...

December 16, 2021

(LOS ANGELES) – The Terasaki Institute for Biomedical Innovation (TIBI) has had a busy and productive year and has grown in many ways.

On the leadership side, TIBI is proud to welcome its new Chief Scientific Officer, Xiling Shen, Ph.D. Dr Shen is a highly accomplished scientist whose works span the multidisciplinary fields of biomedical engineering, computational techniques, cancer biology, and multi-omics methodology.

Read more ...

Fibrous material may be used as antiviral agent in garments, face coverings and bandages

December 16, 2021

(LOS ANGELES) – Billions of people around the world suffer from herpes simplex virus (HSV) infections; the severity of these infections range from no symptoms at all to fatal complications. There are two types of herpes viruses: HSV-1, which infects the eyes and oral cavity, and HSV-2, which infects the genitalia.

Current treatments include antiviral drugs which are either injected or applied topically as ointments; these drugs interfere with virus replication to keep their population in check. Other treatments are available such as vaccines, which stimulate antiviral immune responses, or immune response-modifying drugs.

Read more ...

December 16, 2021

(LOS ANGELES) – Established in 1992, in response to the scientific evidence supporting a rapidly changing global climate, the United Nations Framework Convention on Climate Change (UNFCCC) was adopted and became its own UN entity.

The Conference of the Parties (COP) was established as the primary annual UNFCCC conference dedicated to the intergovernmental climate change negotiations of the 197 parties (countries).

Read more ...